Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Anales De Medicina Interna (Madrid, Spain : 1984)|February 24, 2001
[Meningeal carcinomatosis as first manifestation of carcinoma of the bladder: report of 2 cases]O Juan Vidal, L de Paz Arias, J Catalá Barceló, et al.
Gastroenterologia Y Hepatologia|March 18, 2005
[Chronic diarrhea with uncommon etiology]R Gil Borrás, O Juan Vidal, M I Talavera Encinas, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 19, 2020
Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensusD Isla, J de Castro, R García-Campelo, et al.
World Journal of Clinical Oncology|August 11, 2022
Current treatment landscape for oligometastatic non-small cell lung cancerJavier Garde-Noguera, Margarita Martín-Martín, Andres Obeso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 4, 2021
Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331<sup>☆</sup>D R Spigel, D Vicente, T E Ciuleanu, et al.
ESMO Real World Data and Digital Oncology|July 1, 2026
First-line osimertinib in advanced <i>EGFR</i>-mutated NSCLC: real-world outcomes, clinicogenomic correlates, and oligoprogression management in a multicenter Spanish cohortG Suay, S Cases-Esteban, P Capdevila, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|January 26, 2018
Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patientsJ Garde-Noguera, P Martin-Martorell, M De Julián, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 11, 2018
Correction to: Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patientsJ Garde-Noguera, P Martin-Martorell, M De Julián, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 12, 2018
Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotypingJ Zugazagoitia, I Ramos, J M Trigo, et al.
ESMO Open|May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LAD P Carbone, T-E Ciuleanu, M Cobo, et al.
Pageof 2